Literature DB >> 14529311

3D-ultrasound guided radiation therapy in the post-prostatectomy setting.

Prakash Chinnaiyan1, Wolfgang Tomée, Rakesh Patel, Rick Chappell, Mark Ritter.   

Abstract

Daily transabdominal ultrasound-directed localization has proven valuable in correcting for setup error and organ motion in the treatment of prostate cancer with three-dimensional conformal radiation therapy (3DCRT). The present study sought to determine whether this transabdominal ultrasound technology could also be reliably applied in the post-operative adjuvant or salvage setting to improve the reproducibility of coverage of the intended volumes and to enhance conformal avoidance of adjacent normal structures. Sixteen consecutive patients who received external beam radiotherapy underwent daily localization using an optically guided 3D-ultrasound target localization system (SonArray, Zmed, Inc., Ashland, MA). Six of the above patients were treated in a post-prostatectomy setting, either adjuvantly or for salvage, while the remaining 10 with intact prostates were treated definitively. Because the bladder neck generally approximates the postoperative prostatic fossa, it was used during ultrasound localization as the primary reference structure for the post-prostatectomy patients. For patients treated definitively, the prostate was the primary reference structure. Daily shifts were recorded and port films were taken weekly immediately after ultrasound-based repositioning. By comparing port films taken after ultrasound localization, which evaluates for both set-up error and internal shift, with the original digitally reconstructed radiographs (DRRs), which represents a zero clinical set-up error situation, the degree of variability in organ position was determined. The average absolute, ultrasound-based shifts from the clinical set-up position in the anterior/posterior, lateral, and cranial/caudal directions for the post-prostatectomy patients were 5 +/- 4 mm SD, 3 +/- 3 mm SD, and 3 +/- 4 mm SD over the entire course of treatment, respectively. The average vector length shift was 8 +/- 4 mm SD. For patients treated with an intact prostate, the analogous average absolute shifts in the anterior/posterior, lateral, and cranial/caudal directions were 4 +/- 3 mm SD, 4 +/- 3 mm SD, and 4 +/- 3 mm SD over the entire course of treatment. The average vector length shift was 7 +/- 4 mm SD. Vector length shifts representing interfraction internal motion were estimated by comparing post-ultrasound port films with DRRs. These were 5 +/- 3 mm SD and 4 +/- 4mm SD for post-prostatectomy and intact prostate patients, respectively. These ultrasound-based displacements were not statistically different in patients with an intact prostate versus patients post-prostatectomy (p > 0.1). In conclusion, daily transabdominal 3D-ultrasound localization proved to be a clinically feasible method of correcting for set-up and internal motion displacements. The bladder neck, which serves as an adequate localization reference structure for the prostatic fossa, could be readily ultrasound imaged and repositioned as necessary. Daily internal motion errors that would have occurred if only pre-treatment port films were used were similar in magnitude to those observed for the patients with intact prostates and were of sufficient magnitude to support the use of daily pre-treatment ultrasound localization in the post-prostatectomy setting.

Entities:  

Mesh:

Year:  2003        PMID: 14529311     DOI: 10.1177/153303460300200511

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  8 in total

1.  Adaptive radiation therapy for postprostatectomy patients using real-time electromagnetic target motion tracking during external beam radiation therapy.

Authors:  Mingyao Zhu; Shyam Bharat; Jeff M Michalski; Hiram A Gay; Wei-Hsien Hou; Parag J Parikh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-09-25       Impact factor: 7.038

2.  Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.

Authors:  Tim J Kruser; David F Jarrard; Andrew K Graf; Sean P Hedican; David R Paolone; John D Wegenke; Glenn Liu; Heather M Geye; Mark A Ritter
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

3.  Prostate bed motion during intensity-modulated radiotherapy treatment.

Authors:  Tracy Klayton; Robert Price; Mark K Buyyounouski; Mark Sobczak; Richard Greenberg; Jinsheng Li; Lanea Keller; Dennis Sopka; Alexander Kutikov; Eric M Horwitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-11       Impact factor: 7.038

4.  Magnetic resonance imaging for adaptive cobalt tomotherapy: A proposal.

Authors:  Tomas Kron; David Eyles; L John Schreiner; Jerry Battista
Journal:  J Med Phys       Date:  2006-10

5.  Target localization for post-prostatectomy patients using CT and ultrasound image guidance.

Authors:  Kamen Paskalev; Steven Feigenberg; Rojymon Jacob; Shawn McNeeley; Eric Horwitz; Robert Price; Charlie Ma; Alan Pollack
Journal:  J Appl Clin Med Phys       Date:  2005-11-21       Impact factor: 2.102

6.  An evaluation of the Clarity 3D ultrasound system for prostate localization.

Authors:  Don Robinson; Derek Liu; Stephen Steciw; Colin Field; Helene Daly; Elantholi P Saibishkumar; Gino Fallone; Matthew Parliament; John Amanie
Journal:  J Appl Clin Med Phys       Date:  2012-07-05       Impact factor: 2.102

Review 7.  Post-Prostatectomy Image-Guided Radiotherapy: The Invisible Target Concept.

Authors:  Florent Vilotte; Mickael Antoine; Maxime Bobin; Igor Latorzeff; Stéphane Supiot; Pierre Richaud; Laurence Thomas; Nicolas Leduc; Stephane Guérif; Jone Iriondo-Alberdi; Renaud de Crevoisier; Paul Sargos
Journal:  Front Oncol       Date:  2017-03-09       Impact factor: 6.244

8.  Does Interfraction Cone Beam Computed Tomography Improve Target Localization in Prostate Bed Radiotherapy?

Authors:  Sara Elakshar; James Man Git Tsui; Michael Jonathan Kucharczyk; Nada Tomic; Ziad Simon Fawaz; Boris Bahoric; Joseph Papayanatos; Ahmad Chaddad; Tamim Niazi
Journal:  Technol Cancer Res Treat       Date:  2019-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.